Form 4 for NDRA ENDRA Life Sciences Inc.
Accepted 2021-09-22 00:00:00 ET · period of report 2021-01-28 · accession 0001209191-21-057234 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-09-22 | 2021-01-28 | NDRA | Thornton Michael Milos | CTO | A - Grant | $0.00 | +22.8K | 316.5K | +8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-01-28 | A | A | 22,815 | $0.00 | 316,525 | D | — | — |